华海药业
(600521)
| 流通市值：238.35亿 | | | 总市值：245.04亿 |
| 流通股本：14.67亿 | | | 总股本：15.08亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,247,654,219.7 | 5,128,307,063.04 | 2,498,671,124.15 | 8,308,719,758.46 |
| 营业收入 | 7,247,654,219.7 | 5,128,307,063.04 | 2,498,671,124.15 | 8,308,719,758.46 |
| 二、营业总成本 | 5,940,775,917.63 | 4,142,622,747.05 | 2,099,036,620.37 | 7,096,899,572.91 |
| 营业成本 | 2,705,990,778.14 | 1,948,433,858.93 | 1,006,059,141.64 | 3,288,338,033.17 |
| 税金及附加 | 85,557,966 | 60,131,004.67 | 29,179,915.45 | 96,689,182.57 |
| 销售费用 | 1,349,133,068.97 | 1,007,232,558.46 | 490,541,619.2 | 1,294,781,815.12 |
| 管理费用 | 991,085,356.96 | 651,598,360.07 | 317,687,299.95 | 1,296,849,987.31 |
| 研发费用 | 687,452,738.14 | 439,957,268.69 | 213,856,487.2 | 982,993,900.79 |
| 财务费用 | 121,556,009.42 | 35,269,696.23 | 41,712,156.93 | 137,246,653.95 |
| 其中:利息费用 | 168,613,812.76 | 113,927,857 | 61,813,221.95 | 231,693,740.17 |
| 其中:利息收入 | 46,413,286.8 | 38,888,319.07 | 10,728,565.86 | 39,479,104.34 |
| 加:公允价值变动收益 | -51,794,785.91 | -67,208,314.63 | -58,793,934.03 | -100,248,243.12 |
| 加:投资收益 | -22,389,423.24 | -14,307,016.13 | -7,172,697.37 | -62,651,521.62 |
| 资产处置收益 | 25,370.45 | -390,640.63 | -397,513.34 | -289,686.98 |
| 资产减值损失(新) | -34,678,626.25 | -29,192,853.3 | 2,618,676.48 | -117,176,373.57 |
| 信用减值损失(新) | -10,714,701.59 | -19,604,762.37 | 3,292,135.16 | 7,932,316.98 |
| 其他收益 | 129,626,392.13 | 102,501,014.06 | 35,446,125.12 | 185,152,946.31 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,316,952,527.66 | 957,481,742.99 | 374,627,295.8 | 1,124,539,623.55 |
| 加:营业外收入 | 6,880,190.11 | 6,746,562.28 | 2,018,885.85 | 5,763,053.44 |
| 减:营业外支出 | 12,569,547.63 | 7,802,959.77 | 4,800,804.91 | 29,981,297.05 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,311,263,170.14 | 956,425,345.5 | 371,845,376.74 | 1,100,321,379.94 |
| 减:所得税费用 | 274,015,375.43 | 202,075,398.79 | 97,900,942.19 | 283,072,034.73 |
| 六、净利润 | 1,037,247,794.71 | 754,349,946.71 | 273,944,434.55 | 817,249,345.21 |
| 持续经营净利润 | 1,037,247,794.71 | 754,349,946.71 | 273,944,434.55 | 817,249,345.21 |
| 归属于母公司股东的净利润 | 1,031,268,135.45 | 748,566,030.81 | 270,842,789.22 | 830,466,003.18 |
| 少数股东损益 | 5,979,659.26 | 5,783,915.9 | 3,101,645.33 | -13,216,657.97 |
| (一)基本每股收益 | 0.71 | 0.52 | 0.19 | 0.57 |
| (二)稀释每股收益 | 0.71 | 0.52 | 0.19 | 0.57 |
| 八、其他综合收益 | -6,120,263.49 | 516,199.63 | -493,321.79 | 5,124,020.47 |
| 归属于母公司股东的其他综合收益 | -6,128,737.82 | 532,742.2 | -479,803.78 | 6,517,586.45 |
| 九、综合收益总额 | 1,031,127,531.22 | 754,866,146.34 | 273,451,112.76 | 822,373,365.68 |
| 归属于母公司股东的综合收益总额 | 1,025,139,397.63 | 749,098,773.01 | 270,362,985.44 | 836,983,589.63 |
| 归属于少数股东的综合收益总额 | 5,988,133.59 | 5,767,373.33 | 3,088,127.32 | -14,610,223.95 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |